Expert review of anticancer therapy · 2025
Prevailing challenges in companion diagnostic test development for lung cancer.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lucà Stefano, Celi Alessandra, Cioce Alessandro, Diluvio Anna, Ali Maria, Montella Marco, Della Corte Carminia Maria, Morgillo Floriana, Fiorelli Alfonso, Alì Greta, Franco Renato
Аннотация
INTRODUCTION: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains the leading cause of cancer-related mortality worldwide. Accurate assessment of predictive biomarkers, such as ALK and PD-L1, is essential for personalized therapy and to guide clinical decisions. Companion diagnostic (CDx) tests play a crucial role in this context.
AREAS COVERED: PD-L1 and ALK are key predictive biomarkers for NSCLC treatment. PD-L1 expression on tumor cells (TCs) helps predict responses to anti - PD-1 and anti - PD-L1 treatments, with assays like 22C3 and SP263. ALK rearrangements, detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), helps predict responses to ALK inhibitors like crizotinib. IHC is a practical and cost-effective screening method but combining IHC with molecular techniques such as next-generation sequencing (NGS) or FISH enhances accuracy.
EXPERT OPINION: PD-L1 and ALK are crucial predictive biomarkers for patients with NSCLC. PD-L1 IHC expression predicts response to immune checkpoint inhibitors (ICIs), but its predictive value is not perfect, with some PD-L1-negative patients benefiting from specific therapy. ALK IHC, with confirmatory FISH or NGS, guides tailored treatment. In this context, an integrated predictive approach enables the best clinical and therapeutic management of patients with NSCLC.
AREAS COVERED: PD-L1 and ALK are key predictive biomarkers for NSCLC treatment. PD-L1 expression on tumor cells (TCs) helps predict responses to anti - PD-1 and anti - PD-L1 treatments, with assays like 22C3 and SP263. ALK rearrangements, detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), helps predict responses to ALK inhibitors like crizotinib. IHC is a practical and cost-effective screening method but combining IHC with molecular techniques such as next-generation sequencing (NGS) or FISH enhances accuracy.
EXPERT OPINION: PD-L1 and ALK are crucial predictive biomarkers for patients with NSCLC. PD-L1 IHC expression predicts response to immune checkpoint inhibitors (ICIs), but its predictive value is not perfect, with some PD-L1-negative patients benefiting from specific therapy. ALK IHC, with confirmatory FISH or NGS, guides tailored treatment. In this context, an integrated predictive approach enables the best clinical and therapeutic management of patients with NSCLC.